Beca publicada por el Ministerio italiano de educación, Universidad e investigación 21/06/2015 .
Advanced bone and soft tissue sarcomas (BSTS) still represent an unmet medical need due to their chemoresistance. The DNA repair machinery is crucial in overcoming chemotherapy-induced DNA damage. Trabectedin induces a DNA damage that leads to PARP-1 activation, therefore PARP-1 inhibitor olaparib was shown to increase trabectedin activity in preclinical models of BSTS. Our division is conducting a phase I trial with the combination of trabectedin and olaparib in advanced BSTS (TOMAS trial, NCT02398058 ). To identify determinants of response/resistance to trabectedin and olaparib combination in patients enrolled in TOMAS trial. The winner of the research grant will be involved in: -phase I trial conduction -evaluation of preliminary evidences of activity in order to select the most/less responsive BSTS histotypes to trabectedin and olaparib wherein to explore the metabolic pathways involved with the aim to identify candidate biomarkers of response.
...
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.